Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Combination Chemotherapy Plus Amifostine in Treating Patients With Metastatic or Unresectable Cancer

The recruitment status of this study is unknown because the information has not been verified recently.
Verified May 2006 by National Cancer Institute (NCI).
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00003657
First received: November 1, 1999
Last updated: February 6, 2009
Last verified: May 2006

November 1, 1999
February 6, 2009
July 1998
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00003657 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Combination Chemotherapy Plus Amifostine in Treating Patients With Metastatic or Unresectable Cancer
High Dose Ifosfamide, Carboplatin and Etoposide With Amifostine Chemoprotection

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more that one drug may kill more tumor cells. Chemoprotective drugs, such as amifostine, may protect normal cells from the side effects of chemotherapy.

PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy plus amifostine chemoprotection in treating patients who have metastatic or unresectable cancer and who are undergoing peripheral stem cell transplantation.

OBJECTIVES: I. Describe the toxic effects of ifosfamide, carboplatin, and etoposide (ICE) with amifostine in patients with metastatic or locally unresectable malignancies who are undergoing peripheral stem cell transplantation. II. Describe the pharmacokinetic profile for ifosfamide and its metabolites in patients receiving the maximum tolerated dose of ICE with amifostine. III. Compare the toxic effects of this study with the toxic effects observed on protocol 94-078. IV. Compare the pharmacokinetics of ifosfamide on this study with the pharmacokinetics observed on protocol 94-078.

OUTLINE: Patients undergo peripheral blood stem cell (PBSC) harvest on day -8, followed by ifosfamide IV, carboplatin IV, and etoposide IV (ICE) by 96 hour continuous infusion on days -7 to -4. Patients receive amifostine IV twice a day on days -7 to -3. PBSCs are reinfused on day 0. Filgrastim (G-CSF) is administered subcutaneously beginning on day 0 at least 2 hours after infusion of the stem cells and continuing until blood cell counts recover. Patients are followed monthly for the first 2 months and then for survival.

PROJECTED ACCRUAL: A total of 25 evaluable patients will be accrued for this study within 19 months.

Interventional
Phase 2
Primary Purpose: Treatment
  • Bladder Cancer
  • Brain and Central Nervous System Tumors
  • Carcinoma of Unknown Primary
  • Extragonadal Germ Cell Tumor
  • Head and Neck Cancer
  • Kidney Cancer
  • Lung Cancer
  • Ovarian Cancer
  • Sarcoma
  • Testicular Germ Cell Tumor
  • Unspecified Adult Solid Tumor, Protocol Specific
  • Biological: filgrastim
  • Drug: amifostine trihydrate
  • Drug: carboplatin
  • Drug: etoposide
  • Drug: ifosfamide
  • Procedure: peripheral blood stem cell transplantation
Not Provided
Elias AD, Richardson P, Tretyakov O, et al.: Amifostine with high dose infosfamide, carboplatin, and etoposide (ICE) with hematopoietic STEM cell support. [Abstract] Proceedings of the American Society of Clinical Oncology 19: A197, 2000.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
25
Not Provided
Not Provided

DISEASE CHARACTERISTICS: Histologically proven metastatic or locally unresectable malignancy Patient may be responding to therapy: Stage IIIC/IV or recurrent/refractory ovarian carcinoma (ineligible for other bone marrow or stem cell transplant protocols) Recurrent or refractory germ cell carcinoma Extensive disease small cell lung cancer in partial or complete remission Stage IIIB non-small cell lung cancer responding to chemotherapy Sarcomas in or near complete remission after induction chemotherapy Responsive bladder, head and neck carcinoma, or carcinoma of unknown primary Other tumors without curative or first line therapy (not eligible for phase II or III studies) No active brain or bone marrow metastases

PATIENT CHARACTERISTICS: Age: 18 to 55 Performance status: PS 0-1 Life expectancy: Not specified Hematopoietic: WBC at least 3,000/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin no greater than 1.5 times upper limit of normal (ULN) SGOT less than 2.5 times ULN Renal: Creatinine no greater than 1.5 times ULN Creatinine clearance at least 60 mL/min Cardiovascular: No uncontrolled or severe cardiovascular disease No myocardial infarction within 6 months No congestive heart failure Other: Not pregnant No other serious medical or psychological illnesses No active uncontrolled bacterial, viral, or fungal infection No active duodenal ulcer

PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: Greater than 3 weeks since prior chemotherapy See Disease Characteristics No other concurrent chemotherapy Endocrine therapy: Not specified Radiotherapy: Greater than 1 week since prior radiotherapy No concurrent radiotherapy Surgery: Greater than 1 week since prior surgery (except for biopsies) Other: No barbiturates, dilantin, or cimetidine within 3 weeks of high dose chemotherapy No antihypertensive medications within 24 hours prior to amifostine administration

Both
18 Years to 55 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00003657
CDR0000066750, DFCI-98068, ALZA-97-038-ii, NCI-V98-1491
Not Provided
Not Provided
Dana-Farber Cancer Institute
Not Provided
Study Chair: Paul G.G. Richardson, MD Dana-Farber Cancer Institute
National Cancer Institute (NCI)
May 2006

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP